WO2016175164A1 - シート状小片、その小片を含む発毛促進用シート、並びに、その小片を含む美白及び皺改善剤 - Google Patents
シート状小片、その小片を含む発毛促進用シート、並びに、その小片を含む美白及び皺改善剤 Download PDFInfo
- Publication number
- WO2016175164A1 WO2016175164A1 PCT/JP2016/062899 JP2016062899W WO2016175164A1 WO 2016175164 A1 WO2016175164 A1 WO 2016175164A1 JP 2016062899 W JP2016062899 W JP 2016062899W WO 2016175164 A1 WO2016175164 A1 WO 2016175164A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sheet
- piece
- piece according
- cells
- hair growth
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41G—ARTIFICIAL FLOWERS; WIGS; MASKS; FEATHERS
- A41G5/00—Hair pieces, inserts, rolls, pads, or the like; Toupées
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41G—ARTIFICIAL FLOWERS; WIGS; MASKS; FEATHERS
- A41G5/00—Hair pieces, inserts, rolls, pads, or the like; Toupées
- A41G5/0006—Toupées covering a bald portion of the head
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41G—ARTIFICIAL FLOWERS; WIGS; MASKS; FEATHERS
- A41G5/00—Hair pieces, inserts, rolls, pads, or the like; Toupées
- A41G5/0006—Toupées covering a bald portion of the head
- A41G5/0013—Fastening thereof
- A41G5/0033—Fastening thereof by adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/04—Skin
Definitions
- the present invention relates to a sheet-like piece, a sheet for promoting hair growth containing the piece, and a whitening and wrinkle improving agent. More specifically, a sheet-like piece for locally absorbing a predetermined physiologically active substance and exerting the action of the physiologically active substance, a hair growth promoting sheet containing the piece, and a whitening and wrinkle improving agent About.
- the wig is a disposable wig (hereinafter referred to as a wig that can be used repeatedly on the head so as to cover the entire head, a base sheet in which a flocking material is planted, and an adhesive layer for attaching the base sheet to the scalp.
- a wig that can be used repeatedly on the head so as to cover the entire head, a base sheet in which a flocking material is planted, and an adhesive layer for attaching the base sheet to the scalp.
- partial wig sometimes referred to as “partial wig”) (see Patent Document 1).
- Patent Document 3 hereinafter referred to as “Prior Art 2”.
- Non-Patent Document 3 whitening cosmetics that make stains inconspicuous, wrinkle-removing cosmetics that improve wrinkles, and the like.
- Conventional techniques 1 and 2 are excellent techniques in that, by using a wig, the state of the hair that has been thinned can be made to look like the state before thinning. However, even if the disposable wig proposed in the prior arts 1 and 2 is used, it does not return to the state before the hair becomes thin, so it must be used continuously while changing the state of the hair. There was a problem.
- cosmetics exhibiting a whitening effect have attracted attention, and many types of cosmetics are commercially available (prior art 3), but side effects such as vitiligo have occurred and have become a major problem. It is believed that whitening effect appears when melanin synthesis in skin cells is suppressed, and tyrosinase activity inhibitor is incorporated into cosmetics.
- cosmetics for whitening and wrinkle have problems such as discomfort such as tingling after application, and the effect can be maintained only for a short period. For this reason, social demands for cosmetics for whitening and wrinkle removal are increasing.
- a first aspect of the present invention includes: a base sheet made of an elastic material; a plurality of microneedles containing a physiologically active substance and extending in a direction opposite to the base sheet side; A reservoir layer provided on one surface; an adhesive layer formed in a mesh shape on the surface of the reservoir layer opposite to the base sheet; and opposite to the surface on which the reservoir layer is formed An auxiliary auxiliary layer formed on the surface of the base sheet on the side so as to be peelable, and a tip portion of the microneedle protrudes from the adhesive layer.
- the elastic material is preferably made of a translucent synthetic resin having a moisture permeability and a thickness of less than 0.1 mm.
- the reservoir layer preferably contains a mixture of a water-soluble polymer and a monosaccharide or disaccharide, and a mixture of the physiologically active substance.
- the water-soluble polymer is selected from the group consisting of collagen, gelatin, hyaluronic acid, dextrin, dextran, proteoglycan, sodium chondroitin sulfate, carboxymethylcellulose, hydroxyethylcellulose hyaluronic acid, and physiologically acceptable salts thereof. It is preferably at least one of them.
- the monosaccharide or disaccharide is preferably any one selected from the group consisting of glucose, fructose, sucrose, lactose, trehalose and a mixture of two or more thereof.
- the physiologically active substance is preferably contained in the dental pulp stem cell culture supernatant, and the dental pulp stem cell culture supernatant is preferably lyophilized powder.
- the dental pulp stem cell comprises a combination of (i) at least one gene selected from the group consisting of bmi-1, HPV-E6 and HPV-E7, and (ii) a gene of either hTERT or pTERT. It is preferably an introduced immortalized cell.
- the dental pulp stem cells are preferably derived from humans or pigs.
- the adhesive layer is preferably formed of a medical silicone adhesive.
- the adhesion auxiliary layer is preferably made of a sponge-like member, and the sponge-like member is made of a material selected from the group consisting of urethane, silicon, pulp paper, styrene, vinyl, and cloth. It is preferable.
- a holding member having a frame shape is further provided on the surface of the adhesive layer opposite to the surface on which the reservoir layer is formed, and the holding member protrudes from the adhesive layer. It is preferable to have a thickness longer than the height of the tip of the microneedle.
- the holding member is preferably a plastic or metal sheet-like member. An aluminum member can be adopted as the metal sheet-like member.
- Another aspect of the present invention is a hair growth promoting sheet characterized in that the hair growth promoting sheet comprises the sheet-like piece of the present invention.
- the hair growth promoting sheet comprises the sheet-like piece of the present invention.
- the artificial hair is fixed to the base sheet with an ultraviolet curable resin.
- the base area of the said base sheet is an area equivalent to the surface area of a fingertip.
- the artificial hair penetrates the adhesion auxiliary layer and is implanted in the base sheet.
- the artificial hair penetrates the base sheet and is fixed to the base sheet on the reservoir layer side of the base sheet.
- a frame-shaped holding member that holds the sheet-like piece and has a thickness that is longer than the height of the tip of the microneedle protruding from the adhesive layer in the sheet-like piece. It is preferable to further comprise.
- a holding member is preferably a plastic or metal sheet-like member.
- the metal sheet-like member is preferably made of aluminum.
- Still another embodiment of the present invention is a whitening and wrinkle improving agent comprising the above-mentioned sheet-like piece in which the reservoir layer contains a freeze-dried culture supernatant.
- a holding member for holding the sheet-like piece is further provided, and the holding member is preferably a plastic or metal sheet-like member.
- the metal sheet-like member is preferably made of aluminum.
- a sheet-shaped piece that can be applied to various parts such as the head and face in an appropriate size and can efficiently introduce a physiologically active substance is provided. be able to.
- a hair growth promoting sheet that can promote hair growth in a portion where hair is almost eliminated or thinned, and can be promoted. Furthermore, according to the present invention, it is possible to provide a whitening and wrinkle improving agent that exhibits a whitening effect and a wrinkle improving effect of thinning a spot and wrinkles by being applied to a spotted portion or a deep wrinkled portion. Can do.
- FIG. 1 is a schematic diagram showing the structure of a sheet-like piece of the present invention.
- FIG. 2 is a schematic diagram showing the shape of the microneedle.
- (A) is sectional drawing
- (B) is a perspective view.
- FIG. 3 is a view (No. 1) for explaining a production process of the sheet-like piece of FIG.
- FIG. 4 is a diagram (No. 2) for explaining a production process of the sheet-like piece of FIG.
- FIG. 5 is a graph showing changes over time in the number of individual doublings of immortalized stem cells that produce the culture supernatant used in the production of the hair growth promoting sheet of the present invention.
- FIG. 1 is a schematic diagram showing the structure of a sheet-like piece of the present invention.
- FIG. 2 is a schematic diagram showing the shape of the microneedle.
- (A) is sectional drawing
- (B) is a perspective view.
- FIG. 3 is a view (No. 1) for explaining a production process of
- FIG. 6 is a graph showing whether or not the expression of STRO-1 in the immortalized stem cells decreases as the number of individual doublings (PD) increases.
- FIG. 7 is a diagram showing the results of hematoxylin-eosin staining when it was confirmed whether or not the bone-forming ability of the immortalized stem cells decreased as the number of individual doublings (PD) increased.
- FIG. 8 is a graph showing changes in the individual doubling number of the immortalized stem cells and the bone mass production ability of the new bone of the culture supernatant.
- FIG. 9 is a schematic diagram showing the structure of the hair growth promoting sheet of the present invention that also has the function of a disposable wig.
- 10 is a cross-sectional view of the hair growth promoting sheet of FIG.
- FIG. 11 is a diagram (part 1) for explaining a manufacturing process of the sheet-like piece of FIG.
- FIG. 12 is a diagram (part 2) for explaining a production process of the sheet-shaped piece of FIG.
- FIG. 13 is a figure (A) which shows a mode that artificial hair is planted on a base sheet, and the enlarged view (B) of the B section in (A).
- FIG. 14 is a diagram (No. 3) for explaining a production step of the sheet-like piece of FIG.
- FIG. 15 is a photograph of the hair growth promoting sheet of the present invention attached to the head.
- FIG. 16 is an enlarged view showing the state of the scalp before applying the hair growth promoting sheet of the present invention (A), the state of the scalp after 3 days of wearing (B), and the state of hair growth of the scalp after 7 days of wearing (C). It is a photograph.
- FIG. 17 is a photograph showing changes before and after application of the hair growth promoting sheet of the present invention to the head. (A) shows the change when affixed to the crown, and (B) shows the alopecia areata behind the ear.
- FIG. 14 is a diagram (No. 3) for explaining a production step of the sheet-like piece of FIG.
- FIG. 15 is a photograph of the hair growth promoting sheet of the present invention attached to the head.
- FIG. 16 is an enlarged view showing the state of the scalp before applying
- FIG. 18 is a schematic diagram showing variations in the shape of the whitening and wrinkle improving agent of the present invention.
- (A) is for removing stains
- (B) is for improving wrinkles around the eyes
- (C) is for improving the frying lines
- (D) is a whitening and wrinkle improving agent for wrinkle improvement of the forehead. It is a schematic diagram shown.
- a sheet-like piece 1 includes (a) a base sheet 2 made of an elastic material; (b) a physiologically active substance and a direction opposite to the base sheet 2 side.
- a reservoir layer 4 formed on the surface of one side (-Z direction side) of the base sheet, and a plurality of microneedles 4n extending in the (-Z direction); and (c) the base sheet side of the reservoir layer 4; Is an adhesive layer 5 formed in a mesh shape on the surface on the opposite side ( ⁇ Z direction side); (d) on the surface of the base sheet 2 on the opposite side (+ Z direction side) to the surface on which the reservoir layer is formed And an auxiliary adhesion layer 12 formed so as to be peelable.
- the tip portion of the microneedle 4 n protrudes from the adhesive layer 5.
- the sheet-like piece 1 is arranged to be peelable on the surface of the adhesive layer 5 on the side opposite to the surface on which the reservoir layer 4 is formed (on the ⁇ Z direction side) and has a frame shape.
- H is further provided.
- the holding member H has a thickness longer than the height of the tip portion of the microneedle 4 n protruding from the adhesive layer 5.
- a plurality of sheet-like pieces 1 are placed on a metallic plate-like member or a plastic plate-like member.
- the side surface in the ⁇ Z direction of the holding member H of the sheet-like piece 1 is firmly bonded to the plate-like member with an adhesive.
- the sheet-like piece 1 placed on the plate-like member as described above is peeled off from the plate-like member in a state where the holding member is left on the plate-like member.
- the holding member H is a plastic or metal sheet-like member provided with an annular member having a shape matching the sheet-like piece. It is preferable in terms of weight and cost.
- the holding member is a metal sheet-like member, it is preferable that the holding member is made of aluminum from the viewpoint of ease of processing and the like.
- the elastic material constituting the base sheet 2 has moisture permeability and has three characteristics of a translucent synthetic resin having a thickness of less than 0.1 mm. This is due to the following three reasons.
- the moisture contained in the sweat will later evaporate without evaporating, which may be uncomfortable and may have an adverse effect on the skin.
- the thickness is 0.1 mm or more, it cannot be naturally adhered to the skin, for example, when a hair growth promoting sheet is adhered to the scalp, or a whitening and wrinkle improving agent is applied to the skin. In such a case, unnaturalness remains such that it can be visually recognized that the hair growth promoting sheet is used.
- a translucent material it is not noticeable that the hair growth promoting sheet is used regardless of the position on the skin.
- an elastic material examples include polyurethane resin, silicon resin, nylon resin, and the like, and a silicon material can be preferably used. This is because when the thickness of the semitransparent synthetic resin having moisture permeability is about 20 to about 60 ⁇ m, it has good fit to the skin and it is not noticeable that it is stuck. In addition, when such a raw material is used for the whitening and wrinkle improving agent of the present invention, for example, after applying it to the face, it is possible to apply makeup from above.
- the reservoir layer 4 has a plurality of microneedles 4n extending in the ⁇ Z direction.
- the recesses for forming the microneedles 4n have a conical shape with an upper diameter o1 of about 0.1 to 0.3 mm, a bottom diameter o2 of about 0.03 to 0.05 mm, and a depth t2 of about 0.6 to 1.0 mm. It is preferable that they are arranged.
- the number of the recesses is preferably about 50 to 100 / cm 2 .
- the reservoir layer 4 preferably contains a mixture of a water-soluble polymer and a monosaccharide or disaccharide and a mixture of the physiologically active substances.
- the water-soluble polymer is at least one selected from the group consisting of collagen, gelatin, hyaluronic acid, dextrin, dextran, proteoglycan, sodium chondroitin sulfate, carboxymethylcellulose, hydroxyethylcellulose hyaluronic acid, and physiologically acceptable salts thereof. It is preferable that
- microneedles 4n having an appropriate size can be formed by these components, and a bioactive substance to be described later is efficiently introduced into the skin by the formed microneedles 4n.
- hyaluronic acid it is preferable to use hyaluronic acid.
- the monosaccharide or disaccharide is preferably any one selected from the group consisting of glucose, fructose, sucrose, lactose, trehalose, and a mixture of two or more thereof. From the viewpoint of cost and irritation, it is preferable to use glucose.
- the content of the monosaccharide or disaccharide in the composition of the water-soluble polymer and the monosaccharide or disaccharide is 0.2 to 4% by weight. From the viewpoint of mechanical strength. If the content of monosaccharides or disaccharides exceeds 5%, the dissolution time of the microneedles in the skin becomes too short within 30 minutes, so these contents are preferably 0.2 to 4% by weight.
- the adhesive layer 5 is preferably formed of a medical silicone adhesive. This is because there is no problem that the skin becomes red after being applied and the skin becomes red after being peeled off. Furthermore, it is preferable that the microneedles 4n having an appropriate size protrude from the mesh of the adhesive layer 5 because the physiologically active substance can be efficiently introduced into the skin.
- adhesion auxiliary layer 12 is preferably composed of a sponge-like member, and is a group consisting of urethane, silicon, pulp paper, styrene, vinyl, and cloth because it is inexpensive to handle, safe and low cost. It is preferable that the material is selected from.
- the sheet-like piece 1 described above can be manufactured as follows. First, as shown in FIG. 3A, a base sheet 2, a reservoir layer 4, an adhesion auxiliary layer 12, a holding member H, and various adhesives are prepared.
- the adhesion auxiliary layer 12 is detachably adhered to the + Z direction side surface of the base sheet 2 using a single adhesive to form the laminate 1a shown in FIG.
- Providing the adhesion auxiliary layer 12 in this way is preferable from the viewpoint that the work can be efficiently performed in forming the subsequent reservoir layer 4 and the like.
- the reservoir layer 4 is firmly adhered to the surface of the base sheet 2 on the ⁇ Z direction side using another adhesive to form the laminate 1b shown in FIG.
- the adhesive layer 5 is formed by applying an adhesive in a mesh shape to the portion of the reservoir layer where the microneedles 4n are not formed on the side surface in the ⁇ Z direction, and the laminate 1c is formed as shown in FIG. Form.
- the holding member H is bonded to the ⁇ Z direction side surface of the adhesive layer 5.
- the sheet-like piece 1 is produced.
- the sheet-like piece 1 produced in this way is placed on a ring-shaped sheet holder provided on a metallic plate-like member having a desired thickness and a desired size, or a plastic plate-like member, Product.
- the physiologically active substance contained in the reservoir layer 4 can be obtained as follows. First, dental pulp stem cells used for production of a culture supernatant containing the physiologically active substance are prepared. These stem cells are obtained by introducing a combination of (i) at least one gene selected from the group consisting of bmi-1, HPV-E6 and HPV-E7 and (ii) either hTERT or pTERT gene It is. This is because when a combination of these genes is introduced, dental pulp stem cells can be passaged for more than 100 generations.
- dental pulp stem cell refers to a kind of stem cell contained in a dental nerve having regenerative ability. Because it is protected by a hard material called teeth, it has the property that it does not transmit ultraviolet rays or radiation, and genes are not easily damaged.
- hTERT is a gene encoding human telomere repair enzyme
- pTERT is a gene encoding porcine telomere repair enzyme
- bmi-1 is a gene that produces Bmi-1 (one of the proteins constituting the polycomb complex). Bmi-1 is necessary for the maintenance of hematopoietic stem cells, and hematopoietic stem cells can be increased by enhancing the activity.
- HPV-E6 and E7 are early genes of HPV-16 or HPV-18, and are genes present in an open reading frame that encodes an early gene used by these human papillomaviruses for self-replication.
- the fallen deciduous teeth are sterilized with, for example, chlorohexidine, the crown portion is divided, and the pulp tissue is collected with a dental reamer.
- the collected dental pulp tissue is then subjected to a basic medium, such as Dulbecco's protein containing 5-15% bovine serum (hereinafter sometimes referred to as “CS”) and 50-150 units / mL antibiotics. It is suspended in a method Eagle medium (Dulbecco's Modified Eagle's Medium, hereinafter referred to as “DMEM”).
- DMEM Dulbecco's Modified Eagle's Medium
- the cells are cultured at 37 ° C. for about 2 weeks in a 5% CO 2 incubator. After removing the culture medium, the cells are washed 1 to several times with PBS or the like. Instead of removing the culture medium and washing the cells, the adhesive dental pulp stem cells that formed colonies can also be recovered. Adherent dental pulp stem cells are detached from the dish by treatment with, for example, 0.025-0.1% trypsin and 0.3-1 mM EDTA for several minutes at 37 ° C., and the cells are then collected.
- a culture solution for example, DMEM containing 10% FCS
- the sorted cells are resuspended in, for example, 3 to 6 mL of the above basal medium and seeded in an adherent cell culture dish having a diameter of 4 to 8 cm.
- the cells are cultured at 37 ° C. for about 2 weeks in a 5% CO 2 incubator. After removing the culture medium, the cells are washed 1 to several times with PBS or the like. Instead of removing the culture medium and washing the cells, the adhesive dental pulp stem cells that formed colonies can also be recovered. Adherent dental pulp stem cells are detached from the dish by treatment with, for example, 0.025-0.1% trypsin and 0.3-1 mM EDTA for several minutes at 37 ° C., and the cells are then collected.
- a culture solution for example, DMEM containing 10% FCS
- the adherent cells selected as described above are cultured.
- the dental pulp stem cells obtained as described above are seeded in an adherent cell culture dish and cultured in an incubator under conditions of 5% CO 2 and 37 ° C.
- primary cultured cells (SHED-P) of human deciduous deciduous tooth stem cells can be obtained.
- the subculture is detached and collected from the culture vessel using trypsin and EDTA as described above. Seed in a culture vessel containing
- the sub-conflict refers to a state in which cells adhere to about 70% of the cell attachment surface in the culture vessel.
- the subculture is performed 1 to 8 times, and the selected cells are grown to the required number of cells, for example, about 1 ⁇ 10 7 cells / mL.
- the cells are collected and stored in liquid nitrogen.
- Cells collected from various donors may be stored in the form of dental pulp stem cell banks.
- a combination of at least one gene selected from the group consisting of bmi-1, HPV-E6 and HPV-E7 and (ii) either hTERT or pTERT gene is introduced as follows: can do. First, a plasmid for incorporating the above combination of genes is prepared, and this is incorporated into a shuttle vector, for example, pShuttle®2, and cloning is performed. Thereafter, Escherichia coli is transformed with pShuttle 2, and a kanamycin resistant transformant (hereinafter referred to as “Kn +”) is selected using kanamycin as a marker. This Kn + DNA is purified and the restriction enzyme site is analyzed to identify the produced recombinant.
- Kn + kanamycin resistant transformant
- the expression cassette is excised from the shuttle vector using, for example, PI-SceI and I-CueI, and this expression cassette is ligated to, for example, adenoviral vector DNA, and Adeno-X viral I DNA is obtain.
- the obtained ligation product (Adeno-X viral DNA) is cleaved with, for example, Swa I, and E. coli is transformed with the cleaved product to obtain a transformant.
- ampicillin is used to select and purify ampicillin-resistant heterogeneous transformants (hereinafter referred to as “Amp +”), and the restriction enzyme sites are analyzed to identify recombinants. To do.
- the recombinant adenovirus is then digested with, for example, Pac I, and the resulting fragment is transfected into HEK293 cells to proliferate and collected to determine the titer of the virus.
- the virus is purified and infected with the target cell, SHED-P.
- the HEK293 cell group after virus infection is stained with FITC according to a conventional method, and STRO-1-positive cells are detected using a flow cytometer.
- STRO-1 is considered as one of the markers of pluripotent mesenchymal stem cells in the bone marrow and serves as an indicator of cell immortalization.
- the obtained immortalized stem cells are cultured for 24 to 48 hours under the conditions of 5% CO 2 and 37 ° C. using the above-mentioned basic medium, for example, DMEM supplemented with 10% FBS. Get Qing.
- the culture supernatant can be collected using, for example, a comago pipette.
- the immortalized stem cells of the present invention are insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), transforming growth factor- ⁇ (TGF- ⁇ ), and hepatocyte growth factor HGF. At least two or more growth factors selected from the group consisting of are secreted into the culture supernatant.
- the “growth factor” is a general term for polypeptides that promote cell division or cause morphological changes or hypertrophy. Factors vary depending on the type of cells that produce growth factors, and are roughly classified into epidermal growth factor (EGF), fibroblast growth factor (FGF), nerve growth factor (NGF), tumor growth factor (TGF), and the like.
- receptors on the cell membrane of each cell have tyrosine kinase activity, and when a growth factor binds, the tyrosine residue of the protein is phosphorylated, causing cell proliferation and differentiation.
- growth factors are mesoderm inducers in ontogeny.
- mesoderm inducers in lymphokine ontogeny that regulates the immune system.
- Such growth factors can be quantified by a known ELISA method, microarray method or the like.
- IGF-1 is a polypeptide having a sequence highly similar to that of insulin, and induces a mitogenic reaction or the like in the same manner as insulin in cell culture. It is known to affect the growth of nerve cells.
- VEGF is a group of glycoproteins involved in angiogenesis that forms new blood vessels where there are no blood vessels and angiogenesis that branches from existing blood vessels to form blood vessels during the embryogenesis stage. is there.
- TGF- ⁇ is also a potent growth inhibitory factor for many cells and is closely involved in cell differentiation, migration, and adhesion, ontogeny and tissue remodeling, wound healing, inflammation / immunity, cancer invasion / It plays an important role in a wide range of areas such as metastasis.
- HGF is versatile not only for hepatocytes but also for various cells that promote cell proliferation, promote cell motility, induce anti-apoptosis (cell death), induce morphogenesis, and regenerate and protect other tissues and organs. It has various physiological activities.
- the culture supernatant containing the above growth factors can be obtained by culturing the various stem cells described above in, for example, DMEM supplemented with 15% FCS at 37 ° C. for a predetermined period.
- the stem cell culture supernatant contains about 70 types of proteins in addition to IGF-1, VEGF, TGF- ⁇ , and HGF.
- ethanol precipitation method For example, 45 mL of 100% ethanol is added to and mixed with 5 mL of the culture supernatant and left at -20 ° C. for 60 minutes. Thereafter, the supernatant is removed by centrifugation at 15,000 ⁇ g for 15 minutes at 4 ° C. Next, for example, 10 mL of 90% ethanol is added and stirred well, and again centrifuged at 15,000 ⁇ g for 5 minutes at 4 ° C. The supernatant can be removed and the resulting pellet can be dissolved, for example, in 500 ⁇ L of sterile water. After lysis, the entire amount is collected in a micro test tube and used as a concentrated stem cell culture supernatant.
- the culture supernatant obtained as described above can be freeze-dried according to a conventional method to obtain a composition prepared at the time of use.
- the obtained composition can be used for forming the reservoir layer 4 used in the sheet-like piece 1 of the present invention.
- the water-soluble polymer and monosaccharide or disaccharide are mixed at a predetermined ratio, and the freeze-dried culture supernatant powder is mixed therewith to prepare a reservoir layer forming material.
- a reservoir layer forming material For example, about 0.2 to 4% by weight of glucose or dextran is mixed with a water-soluble polymer such as hyaluronic acid or polyvinyl alcohol, and a desired amount of the lyophilized powder of the culture supernatant is mixed therewith to form a reservoir layer.
- a water-soluble polymer such as hyaluronic acid or polyvinyl alcohol
- a microneedle pattern having a shape as shown in FIG. Thereafter, this pattern is transferred by electroforming to manufacture a mold for forming microneedles.
- This mold is preferably about 8 to 20 cm on a side from the viewpoint of work efficiency.
- the recess for forming the microneedle 4n has a conical shape with an upper diameter o1 of about 0.1 to 0.3 mm, a bottom diameter o2 of about 0.03 to 0.05 mm, and a depth t2 of about 0.6 to 1.0 mm. It is preferable to arrange in a lattice pattern.
- This recess is preferably about 50 to 100 / cm 2 (see FIG. 2 (B)).
- the reservoir layer forming material Water is added to the reservoir layer forming material to prepare an aqueous solution containing about 5 to 20% solids, poured into the mold at room temperature, evaporated to dryness, and then peeled off from the mold As a result, the reservoir layer 4 in which the microneedles 4n are formed can be obtained.
- the sheet-like piece 1 produced as described above can be used as an embodiment of a hair growth promoting sheet or a whitening and wrinkle improving agent by adjusting the amount of the physiologically active substance to be used. . Therefore, in the following description, the sheet-like piece 1 is also referred to as “hair growth promoting sheet 1” or “whitening and wrinkle improving agent 1” as appropriate.
- FIG. 9 shows a structure of a hair growth promoting sheet 10 which is another embodiment of the hair growth promoting sheet.
- the hair growth promoting sheet 10 includes the sheet-shaped piece 1 described above; and a plurality of artificial hairs 6.
- the artificial hair 6 is implanted in the base sheet 2 at a predetermined density as shown in FIG. As shown in FIG. 10, the artificial hair 6 passes through the base sheet 2 and the adhesion assisting layer 12 and is fixed to the base sheet 2 on the ⁇ Z direction side surface of the base sheet 2.
- the above-described hair growth promoting sheet 10 is premised on being used by adhering the whole to the scalp, so it is preferable to use a skin base. Further, the thickness of the hair growth promoting sheet 10 is preferably 20 to 60 ⁇ m from the viewpoint of the balance between good adhesiveness and durability during attachment and detachment, and more preferably 30 to 40 ⁇ m.
- the predetermined density is appropriately determined depending on the hair growth state of the part to which the hair growth promoting sheet 10 is applied.
- the total number of Japanese hair is said to be about 100,000, and the hair density (number per 1 cm 2 ) is 133-249 (average 199) at the top of the hair.
- Measured values of 114-250 (average 183), 137-235 (average 172) in the occipital region, 106-217 temporal portions (average 130) in the occipital region are published. What is necessary is just to select suitably referring to these numbers.
- the artificial hair 6 can use fibers that are generally used for the production of wigs, such as polyester fibers, vinyl chloride fibers, acrylic fibers, flame retardant polyester fibers, and the like. From the aspect, it is preferable.
- the artificial hair 6 is preferably fixed to the base sheet 2 with an ultraviolet curable resin. This is because, by using the UV curable property, the artificial hair 6 planted can be efficiently fixed while preventing the artificial hair 6 from coming off.
- the hair growth promoting sheet 10 described above can be produced as follows. First, as shown in FIG. 11A, a base sheet 2, a reservoir layer 4, an adhesion auxiliary layer 12, a holding member H, a plurality of artificial hairs 6 and various adhesives are prepared.
- the adhesion auxiliary layer 12 is detachably bonded to the + Z direction side surface of the base sheet 2 using one adhesive to form the laminate 1a shown in FIG.
- a plurality of artificial hairs 6 are implanted at a predetermined density so as to penetrate the adhesion assisting layer 12 and the base sheet 2 of the laminated body 1a, thereby producing an intermediate material 10a shown in FIG.
- the artificial hair 6 is implanted into the laminate 1a by a V-type flocking method.
- a pair of guides that can move the artificial hair 6 cut to a certain length in the Z-axis direction on the ⁇ Z direction side of the base sheet 2.
- the needle 15 is locked.
- the guide needle 15 is moved in the + Z direction while the artificial hair 6 is locked.
- the guide needle 15 moves in the + Z direction and is pulled out while leaving the root 6a of the artificial hair 6 on the ⁇ Z direction side of the base sheet 2.
- an ultraviolet curable adhesive is applied to the root 6a remaining on the ⁇ Z direction side of the base sheet 2 and cured by irradiating with ultraviolet rays. In this way, the artificial hair 6 is implanted into the laminate 1a.
- the reservoir layer 4 is firmly bonded to the surface on the ⁇ Z direction side of the base sheet 2 of the intermediate member 10a using an adhesive, and the state shown in FIG. The intermediate material 10b is produced.
- forming the reservoir layer 4 by laminating the above-described uniform layer having the microneedles 4n on the entire back surface of the base sheet 2 ensures improved adhesion and a natural appearance.
- the thickness is about 1.5 to 2 times the thickness of the base sheet 2 (about 45 to 80 ⁇ m) to maintain the tensile strength of the hair growth promoting sheet of the present invention and the artificial hair ( It is sometimes referred to as “hair material.”) 6 is preferable because it can be stabilized.
- the adhesive layer 5 is formed by applying a pressure-sensitive adhesive to the portion of the intermediate material 10b where the microneedles 4n are not formed on the side surface of the reservoir layer 4 in the ⁇ Z direction, and the intermediate layer shown in FIG.
- the material 10c is produced.
- the holding member H is bonded to the ⁇ Z direction side surface of the adhesive layer 5 of the intermediate material 10c.
- the hair growth promoting sheet 10 is produced.
- the hair growth promoting sheet 10 thus produced is placed on a ring-shaped sheet holder provided on a metal plate member having a desired thickness and a desired size, or a plate member made of plastic. And product.
- the hair growth promoting sheet 10 of the present invention has the adhesive layer 5 formed in a lattice shape, it does not unnecessarily suppress the growth of hair appearing from the skin. As a result, prompt hair growth can be realized.
- whitening and A wrinkle improving agent can be produced.
- the produced whitening and wrinkle improving agents can be cut into various sizes depending on the application, as shown in FIGS. 18 (A) to (D), and retained as in the case of the sheet-like piece 1. It can be put on the member H to make a product.
- E. coli competent cells Supercharge EZ10 Electrocompetent Cells, product code 636756), Swa I (product code 1111A, Smi I is equivalent), Xho I (product code 1094A), T4 DNA Ligase (product) Code 2011A), NucleoBond Xtra Midi (product code 740410.10 / .50 / .100), and NucleoSpin Plasmid (product code 740588 10/50/250) were all purchased from Takara Bio Inc. Pac I was purchased from New England Biolabs.
- Buffer 1 25 mM Tris-HCl (pH 8.0) containing 10 mM EDTA and 50 mM glucose (stored at 4 ° C. after autoclaving)
- Buffer 2 0.2M NaOH containing 1% SDS (prepared immediately before use, sealed, and stored at room temperature)
- Buffer 3 5M KOAc (after autoclaving, store at 4 ° C)
- Buffer 4 10 mM Tris-HCl (pH 8.0) containing 1 mM EDTA, 20 ⁇ g / mL RNase (Add RNase immediately before use. Store at -20 ° C)
- HEK293 cells (ATCC # CRL1573) transformed with human type 5 adenovirus were used.
- HEK293 cells were cultured in complete medium.
- the composition of the complete medium was DMEM (Dulbecco's Modified Eagle's Medium, basic medium) supplemented with 100 unit / mL penicillin G sodium, 100 ⁇ g / mL streptomycin, 4 mM L-glutamine and 10% FBS.
- the penicillin G sodium solution was prepared at 10,000 units / mL
- the streptomycin sulfate solution was prepared at 10,000 ⁇ g / mL and stored as a stock solution.
- 60 mm plate, 100 mm plate, 6-well plate, T75 and T175 flasks were used.
- Trypsin-EDTA (product code CC-5012) was purchased from Takara Bio Inc. Phosphate buffered saline (without PBS, Ca2 + and Mg2 + ) and Dulbecco's phosphate buffered saline (with DPBS, Ca2 + and Mg2 + ) were prepared. Further, a 0.33% neutral red staining solution and a 0.4% trypan blue staining solution were used.
- X-Gal (5-bromo-4-chloro-3-indolyl- ⁇ -D-galactopyranoside (25 mg / mL)) dimethylformamide (DMF) solution was stored at ⁇ 20 ° C. protected from light.
- Luminescent ⁇ -gal Detection Kit II (product code 631712, manufactured by Takara Bio Inc.) was used.
- pShuttle2-lacZ positive control vector included in Adeno-X Expression System 1
- Adeno-X Viral DNA PI-Sce I and I-Ceu I digested
- a recombinant adenovirus containing lacZ was constructed according to the attached protocol.
- the target cell, SHED was infected and assayed for ⁇ -galactosidase expression to confirm that the vector was constructed.
- rpShuttle 2 Vector Prior to construction of recombinant pShuttle 2 Vector (hereinafter referred to as “rpShuttle 2 Vector”), DH5 ⁇ was obtained using the pShuttle 2 Vector and pShuttle 2-lacZ Vector included in the kit. E. coli was transformed. A transformant was selected on an LB agar plate (hereinafter referred to as “LB / Kan”) containing 50 ⁇ g / mL kanamycin, and the cells taken from a single colony were streaked to a new LB / Kan. Incubate overnight at ° C.
- LB / Kan LB agar plate
- hTERT, bmi-1, HPV-E6, and HPV-E7 were cloned into pShuttle®2 by the following procedure.
- PShuttle-2 vector was cleaved with restriction enzymes suitable for these genes.
- pShuttle 2 Vector Information Packet PT3416-5 attached to the above kit, a multicloning site matching the DNA to be inserted was determined.
- the above plasmid treated with the restriction enzyme was purified by treatment with alkaline phosphatase.
- the target DNA fragment was prepared and purified according to a conventional method.
- the vector digested with the restriction enzyme and the gene fragment were ligated, and DH5 ⁇ cells (competent cells) were transformed with the ligation product.
- a part of the above competent cells was taken and transformed with the control vector pShuttle2-lacZ Vector included in the kit as a positive control.
- the mixed solution containing transformed E. coli was inoculated on an LB / Kan agar plate, and kanamycin resistant (Kanr) transformants (colony) were selected. Five to ten Kan resistant clones were selected and inoculated into a small amount of liquid medium for amplification. After confirming that these clones had rpShuttle 2 Vector, they were incubated overnight. Thereafter, the constructed plasmid DNA was purified by a conventional method using a commercially available silica adsorption column.
- rpShuttle2 plasmid DNA Recombinant pShuttle 2 plasmid DNA
- rpShuttle2 plasmid DNA was directly transfected into target cells, and Western blotting was performed to preliminarily check the expression of the target protein.
- Phenol chloroform: isoamyl alcohol extraction
- a centrifuge tube add 70 ⁇ L of 1 ⁇ TE Buffer (pH 8.0) and 100 ⁇ L of PCI mixture to the remainder of the double digestion solution (25 ⁇ l), Vortex thoroughly.
- the mixture was centrifuged at 14,000 rpm for 5 minutes at 4 ° C., and the aqueous layer was transferred to a clean 1.5 mL microcentrifuge tube. 400 ⁇ L of 95% ethanol, 25 ⁇ L of 10M ammonium acetate, and 1 ⁇ L of glycogen (20 mg / mL) were added thereto, and the mixture was vortexed well.
- the mixture was centrifuged at 14,000 rpm for 5 minutes at 4 ° C., and the supernatant was removed by aspiration to obtain a pellet.
- 300 ⁇ L of 70% ethanol was added and centrifuged at 14,000 rpm for 2 minutes at room temperature. The supernatant was carefully aspirated off and the pellet was air dried at room temperature for approximately 15 minutes. After the pellets were dried, they were dissolved in 10 ⁇ L of sterilized 1 ⁇ TE Buffer (pH 8.0) and stored at ⁇ 20 ° C. until use.
- the mixture was centrifuged at 14,000 rpm for 5 minutes at 4 ° C., and the supernatant was removed by aspiration to obtain a pellet.
- the following ethanol precipitation operation was performed in the same manner as in the above (3-4). After the pellet dried, it was dissolved in 15 ⁇ L of sterile deionized water.
- Adeno-X plasmid DNA was purified according to the mini-scale method described later.
- the cell suspension was centrifuged at 14,000 rpm for 5 minutes at 4 ° C., and the clear supernatant was transferred to a clean 1.5 mL centrifuge tube.
- 450 ⁇ L of a PCI mixed solution was added, mixed by inversion and stirred. Thereafter, the mixture was centrifuged at 14,000 rpm for 5 minutes at 4 ° C., and the aqueous layer was transferred to a clean 1.5 mL microcentrifuge tube.
- the following ethanol precipitation was performed in the same manner as in (4-1) above, and the pellet solution was stored at ⁇ 20 ° C. until use.
- the target rDNA was identified by restriction enzyme analysis and PCR described below.
- Each culture plate is transfected with 10 ⁇ L of Pac-I-digested Adeno-X plasmid DNA, and AdEK- X DNA was introduced. From the day after transfection, it was confirmed whether CPE (cytopathic effect) occurred. One week later, the cells adhering to the bottom and sides of the culture plate were gently agitated to release them. The resulting cell suspension was transferred to a 15 mL sterilized conical centrifuge tube and centrifuged at 1,500 ⁇ g for 5 minutes at room temperature.
- the obtained precipitate was suspended in 500 ⁇ L of sterile PBS.
- the freeze-thaw operation of freezing in dry ice / ethanol and thawing in a constant temperature bath at 37 ° C. was repeated three times to obtain a lysate in which cells were sufficiently thawed.
- the suspension was lightly centrifuged to remove the suspended matter, and the supernatant was transferred to another sterilized tube and used immediately.
- the portion not used immediately was stored at -20 ° C. 250 ⁇ L of the lysate was added to cultured cells on a 60 mm plate, and the culture was continued.
- CPE was confirmed by culturing at 37 ° C. in the presence of 5% CO 2 for 3 to 4 days.
- a free cell suspension was prepared in the same manner as above and transferred to a 15 mL sterilized conical centrifuge tube. Freezing and thawing operations similar to the above were performed to thaw the cells.
- a titer of 10 7 PFU / mL was obtained using the Adeno-X Rapid Titer Kit (product code 631028). Western blotting was performed to confirm that the packaged adenovirus genome has a functional copy of the transcription unit specific for the gene of interest.
- Adenovirus infection to target cells (7-1) Infection to target cells 6-well plates were inoculated with 1 ⁇ 10 6 SHEDs 24 hours before infection. The day after inoculation, the medium was removed and 1.0 mL of medium containing virus was added to the center of each plate. This solution was spread evenly over the monolayer formed by SHED.
- the cells were cultured at 37 ° C. in the presence of 5% CO 2 for 4 hours, and the virus was infected with SHED. Then, a fresh medium was added and further cultured at 37 ° C. in the presence of 5% CO 2 . Transgene expression was analyzed over time from 24 to 48 hours after infection.
- the cells separated by filtration were resuspended in 4 mL of the above medium and seeded in an adherent cell culture dish having a diameter of 60 mm.
- DMEM containing 10% FCS and (Dulbecco's Modified Eagle's Medium) was added to the dish and about two weeks incubation at adjusted incubator in 5% CO 2, 37 °C.
- the adherent cells (dental pulp stem cells) that formed colonies were treated with 0.05% trypsin / 0.2 mM EDTA for 5 minutes at 37 ° C., and the cells detached from the dish were collected.
- adherent cells selected as described above are seeded in an adherent cell culture dish (collagen-coated dish), primary cultured in an incubator adjusted to 5% CO 2 and 37 ° C., and primary cultured. Cells were used. When the cells become sub-confluent (about 70% of the surface of the culture container) or confluent by visual observation, the cells are treated with 0.05% trypsin and 0.2 mM EDTA for 5 minutes at 37 ° C. It peeled off and collect
- SHED was fixed with 3% paraformaldehyde, rinsed twice with PBS, and treated with 100 ⁇ M glycine for 20 minutes. These cells were then permeabilized with 0.2% Triton-X (Sigma-Aldrich) for 30 minutes and then incubated in a mixture of 5% donkey serum and 0.5% bovine serum albumin for 20 minutes.
- the cells were incubated with a mouse anti-human STRO-1 antibody (1: 100, manufactured by R & D) for 1 hour as a primary antibody, and a goat anti-mouse immunoglobulin M-FITC antibody (1: 500, secondary antibody). Incubated with Southern Biotech) for 30 minutes and mounted using VectorShield DAPI (Vector Laboratories Inc.). Thereafter, ⁇ -MEM supplemented with 15% FBS was placed in a 6-well plate, and the sorted cells were seeded for clone preparation. Approximately 300 colonies from the expanded cells were pooled for testing.
- SHED-T SHED-T
- SHED-C SHED-C
- FIG. 5 shows the doubling state of the number of individuals of SHED-T (SHED into which gene was introduced).
- the vertical axis represents the number of individual doublings (number of cell divisions, times), and the horizontal axis represents time (culture days).
- SHED-C stopped growing after about 30 times, and entered the aging or growth stopping stage.
- SHED-T exceeded 250 PD and proliferated after 800 days.
- SHED-C the proportion of STRO-1 positive cells was 27% in PD20 and decreased to 15% in PD30 (FIGS. 8A and 8B).
- SHED-T the proportion of STRO-1 positive cells was 46% for PD20 and 41% for PD40, respectively (FIGS. 6C and 6D).
- transplant 8 weeks after transplantation, the transplant was collected, fixed with 4% formalin, decalcified, and buffered with a PBS solution containing 10% EDTA for embedding in paraffin. Some were stored in 70% ethanol solution for plastic embedding.
- Paraffin sections were deparaffinized, hydrated, and stained with hematoxylin and eosin (hereinafter referred to as “H & E”).
- 7 (A) to (C) show stained images of PD0 to PD20 of SHED-T (immortalized stem cells), and (D) to (F) of PD0 to PD20 of SHED-C (normal cells). A stained image is shown.
- a specific area was selected, and for each implant formed after SHED-T transplant or SHED-C transplant, And the amount of new bone was determined from these values.
- New bone mass new bone area / visual field area ⁇ 100
- FIG. 8 shows changes in the amount of new bone between SHED-T and SHED-C at each individual doubling number (doubling time).
- ** represents p ⁇ 0.05
- *** represents p ⁇ 0.01.
- the amount of new bone was calculated
- SHED-C the amount of new bone decreased as the number of individuals increased, and with PD20, it decreased to about 1/5 of PD0.
- SHED-T the amount of new bone hardly changed until PD20, and it was shown that in PD20, SHED-T formed more than five times the bone of SHED-C.
- SHED-C and SHED-T cells were transplanted into the subcutaneous tissue of immunocompromised mice. After the transplantation, observation was performed for 30 days or more. During this period, no tumor was formed in any mouse transplanted with the above cells. In SHED-T cells, there was no change in the morphology of all clones of 40-200 PD cultured cells. From the above, it was shown that SHED-T has no carcinogenic activity.
- SHED-T was shown to have the ability to proliferate while maintaining differentiation ability even when exceeding 260 PD, SHED-C was aged at 30 PD or less, although it had differentiation ability. . From the above, it was shown that SHED-T is an immortalized cell and is suitable for mass production of highly active SHED culture supernatant.
- a sheet was formed from a commercially available photosensitive resin, and a microneedle pattern having a shape as shown in FIG. 2A was produced using a photolithography method. Thereafter, this pattern was transferred by electroforming to produce a mold for forming microneedles.
- This mold was a square of about 10 cm square on one side or a rectangle of 7 cm ⁇ 15 cm.
- the recesses for forming the microneedles were arranged in a lattice shape so as to form a conical shape having an upper diameter of about 0.2 mm, a bottom diameter of about 0.04 mm, and a depth of about 0.8 mm.
- the number of the concave portions was about 75 / cm 2 .
- the hair growth promoting sheet 1 produced as described above was produced by the procedure shown in FIGS. 3 (A) to 4 (B).
- the hair growth promoting sheet 1 prepared as described above was attached to a male head as shown in FIG. After the hair growth promoting sheet 1 was applied and adhered to the scalp, the adhesion auxiliary layer was peeled off from the base sheet.
- the results of photographing with a digital camera using a base without a hair material implanted are shown in FIGS. 16 (A) to (C). Shown in
- Fig. 16 (A) shows the state of the hair before application
- Fig. 16 (B) shows the state of the hair 3 to 7 days after application
- Fig. 16 (C) shows 1-3.
- the hair growth promoting sheet of the present invention was applied, hair growth was observed after 3 days, and thereafter it became clear that the amount of hair growth increased over time.
- FIGS. 16 (B) 1 to 3
- FIGS. 16 (C) In particular, in the photograph after 7 days, it was observed that a plurality of hairs were extended from one place (see FIG. 16 (C) 3).
- FIG. 17A shows the change in state when the hair growth promoting sheet of the present invention is applied to the part that has become gray hair.
- the left-hand photo in (A) is the photo before the start of pasting, and the right-hand photo is a photo of about two months after the pasting was performed five times. In the part where hair loss had occurred, only white hair was applied before application, but it was confirmed that the amount of hair growth increased and black hair had grown.
- FIG. 17 (B) shows the change in state when the hair growth promoting sheet of the present invention is applied to the hair removal portion.
- the left-hand photo of (B) is the photo before pasting
- the right-hand photo of (B) is the photo about two months after the pasting. In the area where hair loss had occurred, a slight amount of gray hair remained before being applied, but the amount of hair growth was clearly increased, and it was confirmed that black hair had grown.
- the present invention is extremely useful in the field of beauty.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Textile Engineering (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
しかし、従来技術1及び2で提案されている使い捨てかつらを使用しても、頭髪が薄くなる前の状態に戻る訳ではないため、頭髪の状態の変化に合わせながら、ずっと使用し続けなければならないという問題があった。
しかし、美白や皺取り用の化粧品は、塗布後にひりひりする等の不快感が生じる、短期間しか効果を維持できないといった問題点があった。このため、美白や皺取り用の化粧品に対する、社会的要請が増大しつつある。
すなわち、本願発明の第1の態様は、弾性材料からなるベースシートと;生理活性物質を含有し、かつ、前記ベースシート側とは反対方向に延びる複数のマイクロニードルが形成され、前記ベースシートの一方側の表面上に設けられたリザーバ層と;前記リザーバ層の前記ベースシート側とは反対側の表面上にメッシュ状に形成される接着層と;前記リザーバ層が形成されている面と反対側の前記ベースシートの面上に剥離可能に形成された接着補助層と;を備え、前記マイクロニードルの先端部は、前記接着層から突出している、ことを特徴とするシート状小片である。
また、シート状小片1は、(e)リザーバ層4が形成されている面と反対側(-Z方向側)の接着層5の面上に剥離可能に配置され、枠型形状を有する保持部材Hをさらに備えている。ここで、保持部材Hは、接着層5から突出しているマイクロニードル4nの先端部の高さよりも長い厚みを有している。
保持部材Hは、上記シート状小片1に形成されているマイクロニードル4nを保護するために、シート状小片と一致した形状の環状部材を備えるプラスチック製又は金属製シート状部材であることが製品の重量及びコストの面から好ましい。前記保持部材が金属製シート状部材である場合は、アルミ製であることが加工のし易さ等の点から好ましい
次いで、ベースシート2の-Z方向側表面に他の接着剤を用いてリザーバ層4を強固に接着し、図3(C)に示される積層体1bを形成する。引き続き、リザーバ層の-Z方向側面におけるマイクロニードル4nが形成されていない部分に、メッシュ状に粘着剤を塗布して接着層5を形成し、図4(A)に示されるように積層体1cを形成する。
こうして作製されたシート状小片1を、所望の厚みを有する所望の大きさの金属性の板状部材、又はプラスチック製の板状部材上に設けられたリング状のシートホルダー上に載置し、製品とする。
まず、上記生理活性物質を含む培養上清の産生に使用する歯髄幹細胞を準備する。こうした幹細胞は、(i)bmi-1、HPV-E6及びHPV-E7からなる群から選ばれる少なくとも1種以上の遺伝子と、(ii)hTERT又はpTERTのいずれかの遺伝子との組み合わせを導入したものである。これらの遺伝子の組み合わせを導入すると、歯髄幹細胞を100代以上、継代することができるからである。
まず、上記脱落乳歯を、例えば、クロロヘキシジンで消毒し、歯冠部を分割し、歯科用リーマーにて歯髄組織を回収する。次いで、採取した歯髄組織を、基本培地、例えば、5~15%のウシ血清(calf serum、以下、「CS」ということがある。)及び50~150ユニット/mLの抗生物質を含有するダルベッコ変法イーグル培地(Dulbecco's Modified Eagle's Medium、以下、「DMEM」という。)に懸濁する。
次いで、例えば、10mLの90%エタノールを加えてよく攪拌し、再び、15,000xgで5分間、4℃にて遠心する。上澄みを除去し、得られたペレットを、例えば、500μLの滅菌水に溶解することができる。溶解後、全量をマイクロテストチューブに回収し、濃縮幹細胞培養上清とする。
こうして作製された発毛促進用シート10を、所望の厚みを有する所望の大きさの金属性の板状部材、又はプラスチック製の板状部材上に設けられたリング状のシートホルダー上に載置し、製品とする。
(1)ウイルス導入用ベクターの作製
(1-1)プラスミド抽出用試薬
カナマイシン(Kan)、アンピシリン(Amp)、LB液体培地及びLB寒天培地、グリコーゲン、アガロース、滅菌水、酢酸アンモニウム、酢酸ナトリウム、ドデシル硫酸ナトリウム及びRNase Aを使用した。50mg/mLのカナマイシン(Kan)及びアンピシリン(Amp)を調製し、ストック溶液として-20℃で保存した。グリコーゲンは20mg/mLに調製した。10mg/mLのRNase Aを調製し-20℃で保存した。10M(飽和)酢酸アンモニウム(NH4OAc)、3Mの酢酸ナトリウム(NaOAc;pH5.2)を調製した。
大腸菌コンピテントセル(Supercharge EZ10 Electrocompetent Cells、製品コード 636756)、Swa I(製品コード 1111A、Smi Iが同等品)、Xho I(製品コード 1094A)、T4 DNA Ligase(製品コード 2011A)、NucleoBond Xtra Midi(製品コード 740410.10/.50/.100)、NucleoSpin Plasmid(製品コード 740588 10/50/250)は、いずれもタカラバイオ(株)より購入した。Pac IはNew England Biolabsより購入した。
1×TE Buffer(1mMのEDTAを含む10mM Tris-HCl [pH8.0])、100mM Tris-HCl(pH8.0)で飽和したフェノール:クロロホルム:イソアミルアルコール(25:24:1、以下、「PCI混液」という。)を調製した。エタノールは、100%及び70%で使用した。ミニスケールでの組換えで使用するpAdeno-X プラスミドDNAの精製用に、以下のバッファー1~4を調製した。
バッファー2:1%SDSを含む0.2M NaOH(使用直前に用時調製、密封し、室温保存)
バッファー3:5M KOAc(オートクレーブ後、4℃で保存)
バッファー4:1mM EDTA、20μg/mL RNaseを含む10mM Tris-HCl(pH8.0)
(使用直前にRNaseを添加する。-20℃で保存)
ヒト5型アデノウイルスで形質転換したヒトHEK293細胞(ATCC #CRL1573)を使用した。HEK293細胞は完全培地で培養した。完全培地の組成は、100unit/mLのペニシリンGナトリウムと100μg/mLのストレプトマイシン、4mMLのグルタミン及び10%FBSを添加したDMEM(Dulbecco’s Modified Eagle’s Medium、基本培地)とした。ペニシリンGナトリウム溶液は10,000units/mL、硫酸ストレプトマイシン溶液は10,000μg/mLで調製し、ストック溶液として保存した。培養には、60mmプレート、100mmプレート、6-ウェルプレート、T75及びT175フラスコを使用した。
(3-1)lacZ を含む組換えアデノウイルス(pAdeno-X-lacZ)の構築
10mLの上述した完全培地に、解凍後、DMSOを除去したHEK293細胞を再懸濁し、全量を直径100mmの培養プレートに移した。HEK293細胞が付着した後に培養液を除去し、細胞を滅菌PBSで一度洗浄し、1mLのトリプシン-EDTA溶液を加えて約2分間処理した。次に、10mLの完全培地を加えてトリプシンの反応を止め、穏やかに懸濁した。バイアブルカウントを行って、培養液10mLを入れた直径100mmのプレートに105個の細胞を移し、均一に拡げた。
組換えpShuttle 2 Vector(以下、「rpShuttle 2 Vector」という。)の構築前に、キットに含まれているpShuttle 2 Vector及びpShuttle 2-lacZ VectorでDH5α大腸菌を形質転換した。50μg/mLのカナマイシンを含有するLB寒天プレート(以下、「LB/Kan」という。)上で形質転換体を選択し、単一コロニーからとった菌体を新しいLB/Kanに画線し、37℃で一晩インキュベートした。
上記のようにして作製したrpShuttle 2プラスミドDNAから、導入した遺伝子の発現カセットをPI-Sce I及びI-Ceu Iで切り出した。キットに添付されたプロトコルに記載されたin vitroライゲーション法に従って、切り出した発現カセットをAdeno-X Viral DNAに組み込んだ。rpShuttle 2プラスミドDNAのPI-Sce I/I-Ceu I二重消化液を30μl調製し、下記の表1に記載した試薬を1.5mLの滅菌済みマイクロ遠心チューブに入れて混合した。
遠心チューブに、上述した二重消化液の残り(25μl)に、70μLの1×TE Buffer(pH8.0)と100μLのPCI混液とを添加し、ボルテックスで十分に撹拌した。次いで、微量遠心機を用いて、4℃にて14,000rpmで5分間遠心し、水層を清浄な1.5mLのマイクロ遠心チューブに移した。ここに、400μLの95%エタノール、25μLの10M酢酸アンモニウム、及び1μLのグリコーゲン(20mg/mL)を添加し、ボルテックスで十分に撹拌した。
ペレットが乾燥した後に、これを10μLの滅菌した1×TE Buffer(pH8.0)に溶解し、使用するまで-20℃にて保存した。
(4-1)Adeno-X ウイルスゲノムへの発現カセットのサブクローニング
下記の表2に示す試薬を、順番通りに1.5mLの滅菌済マイクロ遠心チューブに入れ、穏やかに混和し、軽く遠心した後に、16℃にて一晩インキュベートした。
下記表3に示す消化液を調製し、遠心チューブに入れた各サンプルに加えて、2時間、25℃にて、インキュベートした。
エレクトロポレーション用コンピテントセル(大腸菌)を、Supercharge EZ10Electrocompetent Cell(製品コード 636756)を使用して、上記(4-2)で得たSwa I消化産物で形質転換した。形質転換混合液を、LB培地にアンピシリン(終濃度100μg/mL)を加えた寒天プレート(以下、「LB/Amp寒天プレート」という。)に接種し、37℃で一晩インキュベートした。アンピシリン耐性(Ampr)形質転換体として、約106個のコロニーを得た。得られたコロニーを、製品に付属のAdeno-X System PCR Screening Primer Setでチェックした。
対数増殖にある培養液5mLを、14,000rpmで30秒間遠心し、上清を除去した。ペレットを再度10,000rpmで1分間遠心し、マイクロピペットを用いて、上清を除去した。ここに、150μLの上記バッファー1を加えて穏やかにピペッティングし、再懸濁した。この細胞懸濁液に、150μLのバッファー2を添加し、穏やかに転倒混和し、氷上に5分間放置した。冷却した細胞懸濁液に、150μLのバッファー3を加えて、再度転倒混和し、氷上に5分間放置した。
PI-Sce I及びI-Ceu Iを用いて解析を行った。下記の表4に示す試薬を、1.5mLの滅菌済みマイクロ遠心チューブに入れ、30μLのPI-Sce I/I-Ceu I二重消化反応液を加えて、十分に撹拌し、軽く回転させて内容物を集めた。
(6-1)HEK293細胞トランスフェクト用rAdeno-XプラスミドDNAの調製
下記表5に示す試薬等を、1.5mLの滅菌済み遠心チューブに入れて混合し、微量遠心機で軽く遠心した。その後、37℃にて2時間、インキュベートし、rAdeno-XプラスミドDNAのPac I制限酵素処理を行った。
以下のエタノール沈殿の操作は、上記(3-4)と同様に操作を行い、ペレットの溶解液は、使用まで-20℃にて保存した。
上記プラスミドDNAのトランスフェクションの24時間前に、直径60mmの培養プレートあたりの細胞数が1~2×106(およそ100cells/mm2)になるよう、HEK293細胞を接種し、37℃、5%CO2存在下でインキュベートした。
この力価測定を始める約24時間前に、HEK293細胞をT75フラスコに接種し、37℃、5%CO2存在下で一夜培養し、50~70%コンフルエントになっていることを確認した。
翌日、ウイルスを含む新しい培地と交換し、MOI=10で感染させた。37℃、5%CO2存在下で90分間培養した後にフラスコを取り出し、10mLの培地を加えた。
(7-1)標的細胞への感染
感染の24時間前に6-ウェルプレートに1×106個のSHEDを接種した。接種の翌日に培地を取り除き、ウイルスを含む1.0mLの培地を各プレートの中心に添加した。この溶液をSHEDが形成した単層全体に均一に広げた。
Adeno-X-lacZを感染させた接着性細胞におけるβ--ガラクトシダーゼの発現は、Luminescent β-galDetection Kit II(製品コード 631712、クロンテック社製)を使用してアッセイした。
10歳の健常男児から得られた脱落乳歯を使用した。この脱落乳歯をイソジン溶液で消毒した後、歯科用ダイヤモンドポイントを用いて、歯冠を水平方向に切断し、歯科用リーマーを用いて歯髄組織を回収した。得られた歯髄組織を、3mg/mLのI型コラゲナーゼ及び4mg/mLのディスパーゼの溶液中で37℃にて1時間消化した。ついで、この溶液を70mmの細胞ストレーナ(Falcon社製)を用いて濾過した。
上述したように、bmi-1, E6, E7及びhTERTの4つの遺伝子をアデノウイルスベクターに組み込み、これらの遺伝子産物を発現するウイルスベクターを作製した。対照として、これらの遺伝子を組み込んでいない対照ベクターを作製した。
SHED-T(遺伝子導入をしたSHED)の個体数の倍加状態を、図5に示した。図中、縦軸は個体数倍加回数(細胞分裂回数、回)、横軸は時間(培養日数)である。また、培養中のSHEDが1ヶ月間分裂しない状態を、細胞の老化の判断基準とした。SHED-Cは30回程で増殖が停止し、老化又は増殖停止段階に入った。これに対し、SHED-Tは250PDを超え、800日経過後も増殖した。
単一細胞の懸濁液を得るため、接着性の単層細胞をトリプシン/EDTAで消化した。2x105個の細胞に抗STRO-1モノクローナル抗体(1:100)を加えて放置し、FACSCaliburフローサイトメーター(Becton Dickinson社製)を使用して分析した。対応するアイソタイプが同一の対照抗体と比較し、99%以上の割合で蛍光レベルが高い場合に発現が陽性とした。SHED-T及びSHED-Cともに、初期及び後期の継代細胞を固定し、FITC結合STRO-1抗体で染色した。その後、フローサイトメトリーで分析した。試験はそれぞれ二回行なった。SHED-CではSTRO-1陽性細胞の割合がPD20で27%であり、PD30では15%まで減少した(図8(A)及び(B))。SHED-TではSTRO-1陽性細胞の割合が、それぞれPD20で46%、PD40で41%であった(図6(C)及び(D))。
PD0、PD10及びPD20におけるSHED-C及びSHED-Tの分化能を、新生骨量の形成能及び組織染色で調べた。まず、2.0 x 106個のSHED-C又はSHED-Tを、40mgのヒドロキシアパタイト/三カルシウムリン酸(HA/TCP)セラミック粉末(オリンパス工業(株)製)に混合し、10週齢の免疫無防備状態マウス(NIH-bgnu-xid, 雌、Harlan Sprague Dawley社製)の背側表面の皮下に移植した。
新生骨量=新生骨面積/視野面積×100
図8に示されるように、SHED-Cでは個体数倍加回数が増えるについて新生骨量が減少し、PD20ではPD0の約1/5まで低下した。これに対し、SHED-Tでは、PD20まで新生骨量はほとんど変動がなく、PD20では、SHED-TはSHED-Cの5倍以上の骨を形成したことが示された。
SHED-C及びSHED-T細胞を、免疫無防備状態マウスの皮下組織に、1×106を個移植した。移植後、30日以上観察を行ったが、この期間中、上記の細胞を移植したいずれのマウスにおいても、腫瘍は形成されなかった。また、SHED-T細胞では、40~200PDの培養細胞のすべてのクローンの形態に変化はなかった。以上より、SHED-Tには、癌化活性はないことが示された。
SHED-Tは、260PDを超えても分化能力を保ったまま増殖する能力を有していることが示されたが、SHED-Cは、分化能力を有するものの30PD以下で老化した。
以上から、SHED-Tは不死化細胞となっており、活性の高いSHED培養上清の大量生産に適することが示された。
ガラス容器中で、ヒアルロン酸に、約0.2~4重量%のデキストランを混合し、ここに所望量の上記培養上清の凍結乾燥粉末を混合し、リザーバ層形成用材料とした。
また、マイクロニードルを形成するための凹部は、上部直径が約0.2mm、底部直径が約0.04mm、深さが約0.8mmの円錐形状をなすようにし、格子状に配列されるようにした。この凹部は、約75個/cm2であった。
引き続き、図3(C)~図4(B)と同様にして、シート状小片を作成した。すなわち、ベースシート2の片面に接着補助層12を、接着剤を用いて接着させ、接着補助層12を形成していないベースシート2の面上に、リザーバ層4を接着させた。次いで、マイクロニードル4nが形成されていない部分に、メッシュ状に接着層5を形成させ、極薄シートを作製した。この極薄シート上に保持部材Hである固定用ウレタンを重ね、図1に示すようなシート状小片とした。
以上のようにして作製される発毛促進用シート1を、図3(A)~図4(B)に示した手順で作製した。
以上のようにして調製した発毛促進用シート1を、図15に示すように、男性の頭部に貼付した。上記発毛促進用シート1を貼付して頭皮に密着させた後に、接着補助層をベースシートから剥がした。本実施例では、本発明の発毛促進用シートの貼付状態を見やすくするために、ヘア材を植え込んでいないベースを使用し、デジカメで撮影を行なった結果を図16(A)~(C)に示す。
2 ベースシート
4 リザーバ層
5 接着層
6 人工毛髪(ヘア材)
6a 根部(植込部)
6b 自由端部
8 固定部
10 発毛促進用シート
12 接着補助層
15 案内針
H 保持部材
Claims (20)
- 弾性材料からなるベースシートと;
生理活性物質を含有し、かつ、前記ベースシート側とは反対方向に延びる複数のマイクロニードルが形成され、前記ベースシートの一方側の表面上に設けられたリザーバ層と;
前記リザーバ層の前記ベースシート側とは反対側の表面上にメッシュ状に形成される接着層と;
前記リザーバ層が形成されている面と反対側の前記ベースシートの面上に剥離可能に形成された接着補助層と;を備え、
前記マイクロニードルの先端部は、前記接着層から突出している、
ことを特徴とするシート状小片。 - 前記弾性材料は、透湿性を有する厚み0.1mm未満の半透明合成樹脂で構成されている、ことを特徴とする請求項1に記載のシート状小片。
- 前記リザーバ層は、水溶性高分子と単糖類又は二糖類との混合物、及び、前記生理活性物質の混合物を含むことを特徴とする、請求項1に記載のシート状小片。
- 前記水溶性高分子は、コラーゲン、ゼラチン、ヒアルロン酸、デキストリン、デキストラン、プロテオグリカン、コンドロイチン硫酸ナトリウム、カルボキシメチルセルロース、ヒドロキシエチルセルロースヒアルロン酸、及びそれらの生理学的に許容される塩からなる群から選ばれる少なくともいずれかである、ことを特徴とする請求項3に記載のシート状小片。
- 前記単糖類又は二糖類は、グルコース、フルクトース、スクロース、ラクトース、トレハロース及びこれらの2以上の混合物からなる群から選ばれるいずれかである、ことを特徴とする請求項3に記載のシート状小片。
- 前記生理活性物質は、歯髄幹細胞の培養上清中に含まれるものである、ことを特徴とする請求項3に記載のシート状小片。
- 前記歯髄幹細胞の培養上清は凍結乾燥粉末である、ことを特徴とする請求項6に記載のシート状小片。
- 前記歯髄幹細胞は、(i)bmi-1、HPV-E6及びHPV-E7からなる群から選ばれる少なくとも1種以上の遺伝子と、(ii)hTERT又はpTERTのいずれかの遺伝子との組み合わせを導入した不死化細胞である、ことを特徴とする請求項6に記載のシート状小片。
- 前記歯髄幹細胞は、ヒト又はブタ由来である、ことを特徴とする請求項6に記載のシート状小片。
- 前記接着層は、医療用シリコン系接着剤で形成されている、ことを特徴とする請求項1に記載のシート状小片。
- 前記接着補助層は、スポンジ状部材で構成されている、ことを特徴とする請求項1に記載のシート状小片。
- 前記スポンジ状部材は、ウレタン、シリコン、パルプ紙、スチロール、ビニール、及び布からなる群から選ばれる素材で構成されている、ことを特徴とする請求項11に記載のシート状小片。
- 前記リザーバ層が形成されている面と反対側の前記接着層の面上に剥離可能に配置され、枠型形状を有する保持部材をさらに備え、
前記保持部材は、前記接着層から突出しているマイクロニードルの先端部の高さよりも長い厚みを有する、ことを特徴とする請求項1に記載のシート状小片。 - 前記保持部材は、プラスチック製又は金属製シート状部材である、ことを特徴とする請求項13に記載のシート状小片。
- 前記金属製シート状部材は、アルミ製である、ことを特徴とする請求項14に記載のシート状小片。
- 発毛促進用シートにおいて、
請求項1~15のいずれかに記載のシート状小片を備える、
ことを特徴とする発毛促進用シート。 - 前記シート状小片が備えるベースシートに所定の密度で植え込まれた人工毛髪を更に備える、ことを特徴とする請求項16に記載の発毛促進用シート。
- 前記人工毛髪は、紫外線硬化性の樹脂により、前記ベースシートに固定されている、ことを特徴とする請求項17に記載の発毛促進用シート。
- 前記ベースシートの底面積が、指頭の表面積と同等の面積となっている、ことを特徴とする請求項17に記載の発毛促進用シート。
- 請求項7に記載のシート状小片を含む美白及び皺改善剤であって、
前記シート状小片が備えるリザーバ層が、凍結乾燥培養上清を有する、美白及び皺改善剤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017515535A JP6505210B2 (ja) | 2015-04-27 | 2016-04-25 | シート状小片、その小片を含む発毛促進用シート、並びに、その小片を含む美白及び皺改善剤 |
CN201680030191.3A CN107614051B (zh) | 2015-04-27 | 2016-04-25 | 片状小片、包含该小片的生发促进用片、以及包含该小片的美白和皱纹改善剂 |
KR1020177032874A KR102546426B1 (ko) | 2015-04-27 | 2016-04-25 | 시트형상 소편, 그 소편을 포함하는 발모 촉진용 시트, 및 그 소편을 포함하는 미백 및 주름 개선제 |
US15/790,335 US10668261B2 (en) | 2015-04-27 | 2017-10-23 | Sheet-like piece, sheet for promoting hair growth comprising sheet-like piece, and whitening and wrinkle ameliorating agent comprising sheet-like piece |
HK18109297.1A HK1249870A1 (zh) | 2015-04-27 | 2018-07-18 | 片狀小片、包含該小片的生髮促進用片、以及包含該小片的美白和皺紋改善劑 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015090521 | 2015-04-27 | ||
JP2015-090521 | 2015-04-27 | ||
JP2016-079985 | 2016-04-13 | ||
JP2016079985 | 2016-04-13 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/790,335 Continuation US10668261B2 (en) | 2015-04-27 | 2017-10-23 | Sheet-like piece, sheet for promoting hair growth comprising sheet-like piece, and whitening and wrinkle ameliorating agent comprising sheet-like piece |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016175164A1 true WO2016175164A1 (ja) | 2016-11-03 |
Family
ID=57198415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/062899 WO2016175164A1 (ja) | 2015-04-27 | 2016-04-25 | シート状小片、その小片を含む発毛促進用シート、並びに、その小片を含む美白及び皺改善剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10668261B2 (ja) |
JP (1) | JP6505210B2 (ja) |
KR (1) | KR102546426B1 (ja) |
CN (1) | CN107614051B (ja) |
HK (1) | HK1249870A1 (ja) |
WO (1) | WO2016175164A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017078176A1 (ja) * | 2015-11-05 | 2017-05-11 | 株式会社Quarrymen&Co. | 不死化幹細胞、及びその作製方法 |
JP2020139255A (ja) * | 2019-03-01 | 2020-09-03 | 鶯ベンチャーコンサルティング合同会社 | 使い捨てかつら |
JP2020164473A (ja) * | 2019-03-29 | 2020-10-08 | 株式会社再生医学研究所 | 歯髄幹細胞培養上清と毛乳頭幹細胞培養上清とを含む育毛剤およびその製造方法 |
JP7405471B2 (ja) | 2022-01-07 | 2023-12-26 | クアッドメディシン | 粒子付着型マイクロニードル及びその製造方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113786394B (zh) * | 2021-08-21 | 2023-06-16 | 武汉天时维璟微生物科技有限公司 | 一种防治脱发的给药系统及其制备方法及微针贴 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005113300A (ja) * | 2003-10-06 | 2005-04-28 | Puroria:Kk | 使い捨てかつら |
JP2005514179A (ja) * | 2002-01-15 | 2005-05-19 | スリーエム イノベイティブ プロパティズ カンパニー | マイクロニードル装置および製造方法 |
WO2013118877A1 (ja) * | 2012-02-10 | 2013-08-15 | 株式会社ジャパニック | 非ヒト幹細胞の培養上清を原材料とする化粧品又は皮膚再生促進剤、及びタンパク質のイオン導入方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5257533A (en) * | 1975-11-07 | 1977-05-12 | Mitsui Eng & Shipbuild Co Ltd | Induction heater |
JPS607193A (ja) | 1983-06-25 | 1985-01-14 | 古河電気工業株式会社 | 回路基板用半田付炉 |
US6611707B1 (en) * | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
JP3484565B2 (ja) | 1999-09-17 | 2004-01-06 | 株式会社プロピア | 使い捨て用かつら |
CA2536443A1 (en) * | 2003-08-26 | 2005-03-03 | Alza Corporation | Device and method for intradermal cell implantation |
JP4883554B2 (ja) * | 2005-09-27 | 2012-02-22 | 株式会社アデランス | 増毛具及びその製造方法 |
KR101030752B1 (ko) * | 2009-04-09 | 2011-04-26 | 한국생명공학연구원 | 유체전달을 조절할 수 있는 마이크로 니들 유닛 |
JP5771382B2 (ja) | 2010-10-28 | 2015-08-26 | 株式会社プロピア | 再製性使い捨てかつら |
-
2016
- 2016-04-25 JP JP2017515535A patent/JP6505210B2/ja active Active
- 2016-04-25 CN CN201680030191.3A patent/CN107614051B/zh active Active
- 2016-04-25 KR KR1020177032874A patent/KR102546426B1/ko active IP Right Grant
- 2016-04-25 WO PCT/JP2016/062899 patent/WO2016175164A1/ja active Application Filing
-
2017
- 2017-10-23 US US15/790,335 patent/US10668261B2/en active Active
-
2018
- 2018-07-18 HK HK18109297.1A patent/HK1249870A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005514179A (ja) * | 2002-01-15 | 2005-05-19 | スリーエム イノベイティブ プロパティズ カンパニー | マイクロニードル装置および製造方法 |
JP2005113300A (ja) * | 2003-10-06 | 2005-04-28 | Puroria:Kk | 使い捨てかつら |
WO2013118877A1 (ja) * | 2012-02-10 | 2013-08-15 | 株式会社ジャパニック | 非ヒト幹細胞の培養上清を原材料とする化粧品又は皮膚再生促進剤、及びタンパク質のイオン導入方法 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017078176A1 (ja) * | 2015-11-05 | 2017-05-11 | 株式会社Quarrymen&Co. | 不死化幹細胞、及びその作製方法 |
JPWO2017078176A1 (ja) * | 2015-11-05 | 2018-09-27 | 株式会社Quarrymen&Co. | 不死化幹細胞、及びその作製方法 |
US11015171B2 (en) | 2015-11-05 | 2021-05-25 | Quarrymen & Co. Inc. | Immortalized stem cells and method for producing same |
JP2020139255A (ja) * | 2019-03-01 | 2020-09-03 | 鶯ベンチャーコンサルティング合同会社 | 使い捨てかつら |
JP2020164473A (ja) * | 2019-03-29 | 2020-10-08 | 株式会社再生医学研究所 | 歯髄幹細胞培養上清と毛乳頭幹細胞培養上清とを含む育毛剤およびその製造方法 |
JP7405471B2 (ja) | 2022-01-07 | 2023-12-26 | クアッドメディシン | 粒子付着型マイクロニードル及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20180071504A1 (en) | 2018-03-15 |
KR20170141719A (ko) | 2017-12-26 |
CN107614051B (zh) | 2020-10-02 |
US10668261B2 (en) | 2020-06-02 |
KR102546426B1 (ko) | 2023-06-22 |
JPWO2016175164A1 (ja) | 2018-03-15 |
HK1249870A1 (zh) | 2018-11-16 |
JP6505210B2 (ja) | 2019-04-24 |
CN107614051A (zh) | 2018-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016175164A1 (ja) | シート状小片、その小片を含む発毛促進用シート、並びに、その小片を含む美白及び皺改善剤 | |
US10494606B2 (en) | Immortalized stem cell, compositions, preparations and uses thereof | |
Nakashima et al. | Stimulation of reparative dentin formation by ex vivo gene therapy using dental pulp stem cells electrotransfected with growth/differentiation factor 11 (Gdf11) | |
Mills et al. | Stem cell therapy enhances electrical viability in myocardial infarction | |
JP6351799B2 (ja) | 癌治療用医薬組成物の製造方法及びその方法によって製造された癌治療用医薬組成物 | |
CN106163572B (zh) | 用于诱导体细胞直接转分化为血管祖细胞的组合物及其用途 | |
US20080213231A1 (en) | Pluripotent Stem Cell Cloned From Single Cell Derived From Skeletal Muscle Tissue | |
Nakashima et al. | Gene therapy for dentin regeneration with bone morphogenetic proteins | |
Ji et al. | Comparison of chloromethyl-dialkylcarbocyanine and green fluorescent protein for labeling human umbilical mesenchymal stem cells | |
US20100273231A1 (en) | Multipotent mesenchymal stem cells from human hair follicles | |
JP2016516394A (ja) | ヒト線維芽細胞において特徴的な幹細胞であるMuse細胞から容易に分化した機能性メラノサイトの使用 | |
KR20190015153A (ko) | 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학적 조성물 | |
JP6830768B2 (ja) | 創傷被覆剤及び創傷被覆用シート | |
Zhou et al. | Establishment of human hair follicle mesenchymal stem cells with overexpressed human hepatocyte growth factor | |
KR20150108843A (ko) | 고기능 임플란트 재료 | |
Dieterlen et al. | Non-viral gene transfer by nucleofection allows stable gene expression in human neural progenitor cells | |
ES2291793T3 (es) | Uso de fibroblastos diferenciados o un cultivo de fibroblastos primario para la transdiferenciacion en celulas adiposas, celulas oseas y celulas cartilaginosas. | |
JP5963670B2 (ja) | 遺伝子細胞療法のための移植材料 | |
JP5537423B2 (ja) | 哺乳動物への遺伝子導入方法 | |
WO2022244851A1 (ja) | 褥瘡の予防剤及び/又は治療剤 | |
CN117106696A (zh) | 一种汗腺诱导培养基及其应用 | |
ITMI20061498A1 (it) | Metodo per la produzione di cellule staminali multipotenti,relativi kit e usi in campo medico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16786441 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2017515535 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20177032874 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16786441 Country of ref document: EP Kind code of ref document: A1 |